Developments in the management of idiopathic pulmonary fibrosis

Drug and Therapeutics Bulletin

Volumn 53, Issue 7, 2015, Pages 78-81

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AZATHIOPRINE; BENZODIAZEPINE DERIVATIVE; CORTICOSTEROID; NINTEDANIB; OPIATE; PIRFENIDONE; PREDNISOLONE; PREDNISONE; THALIDOMIDE; INDOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ARTICLE; COUGHING; DRUG APPROVAL; DYSPNEA; FIBROSING ALVEOLITIS; HUMAN; LUNG FUNCTION TEST; LUNG LAVAGE; LUNG TRANSPLANTATION; META ANALYSIS (TOPIC); OXYGEN THERAPY; PALLIATIVE THERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PULMONARY REHABILITATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPIROMETRY; THORAX RADIOGRAPHY; TRANSBRONCHIAL BIOPSY; DISEASE COURSE; DRUG MANUFACTURE; IDIOPATHIC PULMONARY FIBROSIS; PATHOPHYSIOLOGY; UNITED KINGDOM;

DISEASE PROGRESSION; DRUG APPROVAL; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; ORPHAN DRUG PRODUCTION; PYRIDONES; UNITED KINGDOM;

EID: 84937011029     PISSN: 00126543     EISSN: 17555248     Source Type: Journal    
DOI: 10.1136/dtb.2015.7.0337     Document Type: Article

References (36)

1. National Institute for Health and Care Excellence, 2013. Idiopathic pulmonary fibrosis: the diagnosis and management of suspected idiopathic pulmonary fibrosis (CG 163) [online]. Available: https://www.nice.org.uk/guidance/cg163 [Accessed 17 June 2015].
2. Behr J. The diagnosis and treatment of idiopathic pulmonary fibrosis. Dtsch Arztebl Int 2013; 110: 875-81.
3. European Medicines Agency, 2015. Orphan designation [online]. Available: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/ general_content_000029.jsp&mid=WC0b01ac05800240ce [Accessed 17 June 2015].
4. Esbriet 267mg Hard Capsules. Summary of product characteristics, UK. Roche Registration Limited, March 2015.
5. Ofev 150mg soft capsules. Summary of product characteristics, EU. Boehringer Ingelheim International GmbH, January 2015.
6. Loveman E et al. The clinical effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: a systematic review and economic evaluation. Health Technol Assess 2015; 19: 1-336.
7. Thickett DR et al. Improving care for patients with idiopathic pulmonary fibrosis (IPF) in the UK: a round table discussion. Thorax 2014; 69: 1136-40.
8. Raghu G et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
9. Navaratnam V et al. Presence of a prothrombotic state in people with idiopathic pulmonary fibrosis: a population-based case-control study. Thorax 2014; 69: 207-15.
10. Navaratnam V et al. The rising incidence of idiopathic pulmonary fibrosis in the U.K. Thorax 2011; 66: 462-7.
11. Ryu JH et al. Idiopathic pulmonary fibrosis: evolving concepts. Mayo Clin Proc 2014; 89: 1130-42.
12. National Clinical Guideline Centre, 2013. Diagnosis and management of suspected idiopathic pulmonary fibrosis [online]. Available: https://www.nice. org.uk/guidance/cg163/documents/idiopathic-pulmonary-fibrosis-full-version2 [Accessed 17 June 2015].
13. Dowman L et al. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev 2014; 10: CD006322. DOI:10.1002/14651858.CD006322.pub3 [Last assessed as up-to-date 27 June 2014].
14. Ryerson CJ et al. Cough predicts prognosis in idiopathic pulmonary fibrosis. Respirology 2011; 16: 969-75.
15. Hope-Gill BD et al. A study of the cough reflex in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168: 995-1002.
16. Horton MR et al. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. Ann Intern Med 2012; 157: 398-406.
17. Smith J et al. Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease. J Allergy Clin Immunol 2006; 117: 831-5.
18. Chang AB et al. Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults. Cochrane Database Syst Rev 2011; 1: CD004823. DOI:10.1002/14651858.CD004823.pub4 [Last assessed as up-to-date 9 June 2010].
19. Swinburn CR et al. Symptomatic benefit of supplemental oxygen in hypoxemic patients with chronic lung disease. Am Rev Respir Dis 1991; 143: 913-5.
20. Nishiyama O et al. Effect of ambulatory oxygen on exertional dyspnea in IPF patients without resting hypoxemia. Respir Med 2013; 107: 1241-6.
21. Crockett AJ et al. Domiciliary oxygen for interstitial lung disease. Cochrane Database Syst Rev 2001; 3: CD002883. DOI:10.1002/14651858.CD002883 [Last assessed as up-to-date 27 October 2010].
22. Jennings AL et al. A systematic review of the use of opioids in the management of dyspnoea. Thorax 2002; 57: 939-44.
23. Castria D et al. Pulmonary hypertension in idiopathic pulmonary fibrosis: prevalence and clinical progress. Int J Immunopathol Pharmacol 2012; 25: 681-9.
24. National Institute for Health and Care Excellence, 2013. Pirfenidone for treating idiopathic pulmonary fibrosis (TA 282) [online]. Available: http://www.nice.org. uk/guidance/TA282 [Accessed 17 June 2015].
25. Noth I et al. Idiopathic Pulmonary Fibrosis Clinical Research Network. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 186: 88-95.
26. Demedts M et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353: 2229-42.
27. Raghu G et al; Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366: 1968-77.
28. Martinez FJ et al; Idiopathic Pulmonary Fibrosis Clinical Research Network. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2093-101.
29. Schaefer CJ et al. Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev 2011; 20: 85-97.
30. Azuma A et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005; 171: 1040-7.
31. Taniguchi H et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 821-9.
32. Noble PW et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760-9.
33. King TE Jr et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083-92.
34. Scottish Medicines Consortium, 2013. Pirfenidone (Esbriet) [online]. Available: http://www.scottishmedicines.org.uk/SMC_Advice/Advice/835_13_pirfenidone_ Esbriet/pirfenidone_Esbriet [Accessed 17 June 2015].
35. Richeldi L et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011; 365: 1079-87.
36. Richeldi L et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071-82.